{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T23:35:07Z","timestamp":1787960107433,"version":"build-2784847793"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T00:00:00Z","timestamp":1683676800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006939","name":"Emory University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006939","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.jgar.2023.05.002","type":"journal-article","created":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T07:27:04Z","timestamp":1684135624000},"page":"360-367","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Evaluation of in vitro activity of ceftaroline against pathogens associated with community-acquired pneumonia: ATLAS program 2017\u20132019"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2811-3069","authenticated-orcid":false,"given":"Eric","family":"Utt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Kantecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4116-4736","authenticated-orcid":false,"given":"Guillermo","family":"Cabezas-Camarero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2023.05.002_bib0001","first-page":"494","article-title":"The incidence rate and economic burden of community-acquired pneumonia in a working-age population","volume":"6","author":"Broulette","year":"2013","journal-title":"Am Health Drug Benefits"},{"key":"10.1016\/j.jgar.2023.05.002_bib0002","unstructured":"World Health Organization. WHO reveals leading causes of death and disability worldwide: 2000\u20132019. https:\/\/www.who.int\/news\/item\/09-12-2020-who-reveals-leading-causes-of-death-and-disability-worldwide-2000-2019 [accessed 25 January 2022]."},{"key":"10.1016\/j.jgar.2023.05.002_bib0003","unstructured":"World Health Organization. The top 10 causes of death. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/the-top-10-causes-of-death [accessed 25 January 2022]."},{"key":"10.1016\/j.jgar.2023.05.002_bib0004","unstructured":"World Health Organization. Pneumonia. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/pneumonia [accessed 25 January 2022]."},{"key":"10.1016\/j.jgar.2023.05.002_bib0005","unstructured":"World Health Organization. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics, 2017. https:\/\/www.who.int\/news\/item\/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed [accessed 25 January 2022]."},{"key":"10.1016\/j.jgar.2023.05.002_bib0006","doi-asserted-by":"crossref","first-page":"20S","DOI":"10.1183\/09031936.02.00702002","article-title":"Community-acquired pneumonia in Europe: causative pathogens and resistance patterns","volume":"36","author":"Woodhead","year":"2002","journal-title":"Eur Respir J"},{"issue":"7","key":"10.1016\/j.jgar.2023.05.002_bib0007","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","article-title":"Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America","volume":"200","author":"Metlay","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jgar.2023.05.002_bib0008","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s40121-014-0036-8","article-title":"Ceftaroline fosamil for the treatment of community-acquired pneumonia: from FOCUS to CAPTURE","volume":"3","author":"Carreno","year":"2014","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.jgar.2023.05.002_bib0009","first-page":"1","article-title":"Safety and efficacy of ceftaroline fosamil in the management of community-acquired bacterial pneumonia","volume":"6","author":"DeBellis","year":"2014","journal-title":"Clin Med Rev Ther"},{"key":"10.1016\/j.jgar.2023.05.002_bib0010","unstructured":"European Medicines Agency (EMA). Zinforo: European public assessment report (EPAR) \u2014 product information. EMEA\/H\/C\/002252. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/zinforo-epar-product-information_en.pdf [accessed 25 January 2022]."},{"key":"10.1016\/j.jgar.2023.05.002_bib0011","unstructured":"TEFLARO. Highlights of prescribing information. https:\/\/media.allergan.com\/actavis\/actavis\/media\/allergan-pdf-documents\/product-prescribing\/Teflaro-USPI-09_2019-2.pdf. [accessed 25 January 2022]."},{"key":"10.1016\/j.jgar.2023.05.002_bib0012","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.diagmicrobio.2016.06.017","article-title":"Antimicrobial susceptibility patterns of community- and hospital-acquired methicillin-resistant Staphylococcus aureus from United States hospitals: results from the AWARE Ceftaroline Surveillance Program (2012\u20132014)","volume":"86","author":"Sader","year":"2016","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"Suppl 3","key":"10.1016\/j.jgar.2023.05.002_bib0013","first-page":"iii19","article-title":"FOCUS 1: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia","volume":"66","author":"File","year":"2011","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 3","key":"10.1016\/j.jgar.2023.05.002_bib0014","doi-asserted-by":"crossref","first-page":"iii33","DOI":"10.1093\/jac\/dkr097","article-title":"FOCUS 2 investigators. FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia","volume":"66","author":"Low","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2023.05.002_bib0015","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S1473-3099(14)71018-7","article-title":"Ceftaroline fosamil versus ceftriaxone for the treatment of Asian patients with community-acquired pneumonia: a randomised, controlled, double-blind, phase 3, non-inferiority with nested superiority trial","volume":"15","author":"Zhong","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jgar.2023.05.002_bib0016","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1097\/INF.0000000000001160","article-title":"A multicenter, randomized, observer-blinded, active-controlled study evaluating the safety and effectiveness of ceftaroline compared with ceftriaxone plus vancomycin in pediatric patients with complicated community-acquired bacterial pneumonia","volume":"35","author":"Blumer","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.jgar.2023.05.002_bib0017","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1097\/INF.0000000000001159","article-title":"A randomized, prospective study of pediatric patients with community-acquired pneumonia treated with ceftaroline versus ceftriaxone","volume":"35","author":"Cannavino","year":"2016","journal-title":"Pediatr Infect Dis J"},{"issue":"Suppl 1","key":"10.1016\/j.jgar.2023.05.002_bib0018","doi-asserted-by":"crossref","first-page":"i31","DOI":"10.1093\/jac\/dkt024","article-title":"Comparison of pathogens and their antimicrobial resistance patterns in paediatric, adult and elderly patients in Canadian hospitals","volume":"68","author":"Adam","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2023.05.002_bib0019","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1093\/jac\/dkaa065","article-title":"Progress towards a coordinated, national paediatric antimicrobial resistance surveillance programme: Staphylococcus aureus, enterococcal and Gram-negative bacteraemia in Australia","volume":"75","author":"Campbell","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2023.05.002_bib0020","article-title":"Incidence, etiology, and environmental risk factors of community-acquired pneumonia requiring hospitalization in China: a 3-year, prospective, age-stratified, multicenter case-control study","volume":"8","author":"Qin","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2023.05.002_bib0021","doi-asserted-by":"crossref","first-page":"114843","DOI":"10.1016\/j.diagmicrobio.2019.05.015","article-title":"Activity of ceftaroline against pathogens associated with community-acquired pneumonia collected as part of the AWARE surveillance program, 2015\u20132016","volume":"95","author":"Bae","year":"2019","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2023.05.002_bib0022","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.diagmicrobio.2016.07.012","article-title":"In vitro activity of Ceftaroline against bacterial pathogens isolated from patients with skin and soft tissue and respiratory tract infections in African and Middle Eastern countries: AWARE global surveillance program 2012\u20132014","volume":"86","author":"Karlowsky","year":"2016","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2023.05.002_bib0023","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ijid.2018.10.004","article-title":"Antimicrobial activity of ceftaroline and comparator agents tested against organisms isolated from patients with community-acquired bacterial pneumonia in Europe, Asia, and Latin America","volume":"77","author":"Sader","year":"2018","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jgar.2023.05.002_bib0024","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/s13756-020-00829-z","article-title":"Global trends of antimicrobial susceptibility to ceftaroline and ceftazidime-avibactam: a surveillance study from the ATLAS program (2012\u20132016)","volume":"9","author":"Zhang","year":"2020","journal-title":"Antimicrob Resist Infect Control"},{"key":"10.1016\/j.jgar.2023.05.002_bib0025","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.2147\/IDR.S226649","article-title":"In vitro activity of ceftaroline and comparators against staphylococcus aureus isolates: results from 6 years of the ATLAS program (2012 to 2017)","volume":"12","author":"Zhang","year":"2019","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.jgar.2023.05.002_bib0026","doi-asserted-by":"crossref","DOI":"10.1093\/jacamr\/dlab159","article-title":"Mohamed N Evaluation of the in vitro activity of ceftaroline, ceftazidime\/avibactam and comparator antimicrobial agents against clinical isolates from paediatric patients in Kuwait: ATLAS data 2012\u201319","volume":"3","author":"Al-Sweih","year":"2021","journal-title":"JAC Antimicrob Resist"},{"key":"10.1016\/j.jgar.2023.05.002_bib0027","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/INF.0000000000001477","article-title":"Ceftaroline activity tested against bacterial isolates causing community-acquired respiratory tract infections and skin and skin structure infections in pediatric patients from United States hospitals: 2012\u20132014","volume":"36","author":"Pfaller","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.jgar.2023.05.002_bib0028","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ijid.2021.04.014","article-title":"Tedizolid activity against a multicentre worldwide collection of Staphylococcus aureus and Streptococcus pneumoniae recovered from patients with pneumonia (2017\u20132019)","volume":"107","author":"Carvalhaes","year":"2021","journal-title":"Int J Infect Dis"},{"issue":"Suppl 3","key":"10.1016\/j.jgar.2023.05.002_bib0029","doi-asserted-by":"crossref","first-page":"S181","DOI":"10.1093\/cid\/cis560","article-title":"Activity analyses of staphylococcal isolates from pediatric, adult, and elderly patients: AWARE Ceftaroline Surveillance Program","volume":"55","author":"Sader","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2023.05.002_bib0030","unstructured":"ATLAS Surveillance. Antimicrobial testing leadership and surveillance. https:\/\/atlas-surveillance.com\/[accessed 20 January 2022]."},{"key":"10.1016\/j.jgar.2023.05.002_bib0031","series-title":"M100 Performance Standards for Antimicrobial Susceptibility Testing","year":"2020"},{"key":"10.1016\/j.jgar.2023.05.002_bib0032","unstructured":"European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters \u2013 version 12.0, valid from 2022-01-01. https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/v_12.0_Breakpoint_Tables.pdf [accessed 27 January 2022]."},{"key":"10.1016\/j.jgar.2023.05.002_bib0033","unstructured":"Tygacil. Package insert. https:\/\/www.pfizer.com\/products\/product-detail\/tygacil [accessed 27 January 2022]."},{"issue":"Suppl 3","key":"10.1016\/j.jgar.2023.05.002_bib0034","first-page":"iii69","article-title":"Comparative ceftaroline activity tested against pathogens associated with community-acquired pneumonia: results from an international surveillance study","volume":"66","author":"Jones","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2023.05.002_bib0035","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1093\/ofid\/ofy270","article-title":"Twenty-year trends in antimicrobial susceptibilities among Staphylococcus aureus from the SENTRY Antimicrobial Surveillance Program","volume":"6","author":"Diekema","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2023.05.002_bib0036","first-page":"125","article-title":"In vitro activity of ceftaroline against methicillin-resistant and methicillin-susceptible Staphylococcus aureus clinical isolates from a tertiary hospital in Greece","volume":"44","author":"Tychala","year":"2021","journal-title":"New Microbiol"},{"key":"10.1016\/j.jgar.2023.05.002_bib0037","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1128\/AAC.02557-13","article-title":"Antimicrobial activity of ceftaroline tested against drug-resistant subsets of Streptococcus pneumoniae from U.S. medical centers","volume":"58","author":"Flamm","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2023.05.002_bib0038","doi-asserted-by":"crossref","first-page":"e01555","DOI":"10.1128\/AAC.01555-17","article-title":"In vitro activities of ceftaroline and comparators against streptococcus pneumoniae isolates from U.S. hospitals: results from seven years of the AWARE Surveillance Program (2010 to 2016)","volume":"62","author":"Pfaller","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2023.05.002_bib0039","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.2147\/IDR.S203121","article-title":"Antimicrobial susceptibility among Streptococcus pneumoniae and Haemophilus influenzae collected globally between 2015 and 2017 as part of the Tigecycline Evaluation and Surveillance Trial (TEST)","volume":"12","author":"Zhang","year":"2019","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.jgar.2023.05.002_bib0040","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s40272-021-00468-w","article-title":"Ceftaroline fosamil for treatment of pediatric complicated skin and soft tissue infections and community-acquired pneumonia","volume":"23","author":"Esposito","year":"2021","journal-title":"Pediatric Drugs"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716523000784?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716523000784?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T10:00:45Z","timestamp":1761991245000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716523000784"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":40,"alternative-id":["S2213716523000784"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2023.05.002","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of in vitro activity of ceftaroline against pathogens associated with community-acquired pneumonia: ATLAS program 2017\u20132019","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2023.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Pfizer Inc and The Author(s). Published by Elsevier Ltd. On behalf of International Society for Chemotherapy of Infection and Cancer.","name":"copyright","label":"Copyright"}]}}